The United Kingdom and the United States have announced a significant bilateral deal that will ensure zero import taxes on British pharmaceutical shipments entering the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has pledged to boost funding on drugs through the NHS. This pledge secures that duties on these vital products will be held at zero for a period of 36 months.
This development is in response to earlier statements to significantly raise import taxes on patented drug imports, with increases mentioned as high as 100%.
"This arrangement between the UK bolsters the global environment for innovative medicines and brings much-needed equity to American-British drug exports," a statement said.
Trade Importance
Medicines represent one of the Britain's largest exports to the United States, which is easily the primary destination for major companies like GSK and AstraZeneca.
Trade data indicate that in the year to the end of September, the UK sold pharmaceutical products valued at £11.1bn to the US. This value represented a significant portion of total UK exports in that timeframe.
"This agreement secures work, stimulates capital expenditure and facilitates the UK to become a worldwide center for medical research," a government official stated.
Specific UK Commitments
The deal entails several notable pledges from the UK:
- Revised Affordability Limit: The UK will raise the affordability limit at which it judges new therapies to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a aim to raise total health service expenditure on medicines from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage manufacturers must return to the NHS to control costs will be restricted at fifteen percent. In the past, rebates were more than 20%.
Recent Tensions
This agreement takes place against a long-running tension between the sector and the UK government over drug pricing and approval rates.
The disagreement were intensified by arguments that American consumers were paying significantly more for the same drugs than patients in the UK and Europe.
In recent months, several large drug company projects in the UK have been halted or scrapped, while substantial expansions have been pledged toward American operations.
The Science Minister acknowledged that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the past decade.
